Last reviewed · How we verify
NCT06078761: HEAL BC
Healthy Eating and Active Lifestyle (HEAL): Breast Cancer Program Outcomes
trial testing Healthy Eating Active Lifestyle (HEAL) Program in Breast Cancer in 22 participants. Completed in 26 February 2026.
1 November 2025
Quick facts
| Lead sponsor | AdventHealth |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 22 |
| Start date | 21 September 2023 |
| Primary completion | 1 November 2025 |
| Estimated completion | 26 February 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Healthy Eating Active Lifestyle (HEAL) Program
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
AdventHealth — full company profile →
Who can join
18 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this single-group prospective study is to examine the impact of the Healthy Eating and Active Lifestyle (HEAL) Breast Cancer program on participants' perceived stress, biometrics, basic labs, lifestyle behaviors, self-efficacy, mental health, and quality of life. Participants will participate in an 8-week program of 90-minute virtual sessions each week to decrease risk of cancer recurrence. Program participants can choose to participate in the research study which will include data collection (surveys, biometrics, basic labs). The data collection will occur at four timepoints - baseline prior to program start, post-program, 3 month follow-up, and 6 month follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06078761
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other AdventHealth trials
Trials by the same sponsor.
- NCT07359352 — Surgical Care And Recovery With Laser Evaluation Trial (SCARLET) · NA · not yet recruiting
- NCT07472127 — Professional Readiness Through Emotional Preparedness (PREP) · NA · not yet recruiting
- NCT07357376 — Evaluating Suzetrigine for Pain Control Following TKA · Phase 3 · not yet recruiting
- NCT07298018 — A Pilot Study of RISE for Nurse Managers Retreat · NA · recruiting
- NCT07081542 — Comparative Analysis of Hearing Outcomes: Robotic vs. Manual Insertion of Cochlear Implants · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06078761 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AdventHealth
- Last refreshed: 13 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06078761.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing